You are here: Industry Insights > COVID-19

News List

COVID-19 can trigger self-attacking antibodies WorldPharmaNews
January 04, 2022
Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all...
Treatments in weeks, not months: Scientists develop ambitious pandemic response plan WorldPharmaNews
January 04, 2022
An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed new and better treatments ...
UK life sciences trade group calls for oral Covid-19 antiviral investment Pharmaceutical-Technology
January 04, 2022
The UK government must invest in Covid-19 antiviral treatments like it did with vaccines, said the chair of the UK BioIndustry Association.
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19 Pharmaceutical-Technology
January 04, 2022
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by 89%.
Novavax files Covid-19 vaccine data with FDA ahead of EUA application Pharmaceutical-Technology
January 04, 2022
Novavax has submitted the final data package with the US Food and Drug Administration (FDA) to satisfy the requirements for seeking emergency use authorization (EUA) for its Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.
CDC Backs Boosters for High-Risk Children Ages 5 to 11 Years drugs
January 04, 2022
The U.S. Centers for Disease Control and Prevention on Tuesday backed the emergency use approval of the Pfizer COVID-19 booster shot for high-risk children between the ages of 5 and 11 years.
Evotec Receives German Grant for Potential Therapy Against COVID-19 contractpharma
January 04, 2022
Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.
MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill pharmatimes
January 04, 2022
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
Hip Fracture Surgery Generally Lower During COVID-19 Pandemic drugs
January 03, 2022
Among older individuals, hip fracture surgery volumes were generally lower during the COVID-19 pandemic than two years earlier until the COVID-19 vaccine became available.
Negative COVID-19 Test May Be Required After Isolation Among Asymptomatic drugs
January 03, 2022
Right now, Americans who have tested positive for COVID-19 but have no symptoms are advised by the U.S. Centers for Disease Control and Prevention to isolate for five days and then wear a mask for another five days when around others.